NCT07671924: The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)
- State
- Under way
- Phase
- Phase 2
- People
- 100 planned
- Started
- 22 Jun 2026
- Primary completion
- Sep 2027
- Arms
- NAL ER 54 mg BID, NAL ER 27 mg BID, NAL ER 27 mg QD
- Results
- None posted
- 22 Jun 2026: Trial started
- 26 Jun 2026: Trial registered